Matthew P. Miller - Concepedia

Author

Matthew P. Miller

Blue Earth Diagnostics (United Kingdom)ORCID

Also Known As

Matthew Miller, Matthew P. Miller

Publications

909

Citations

H-Index

Concepts

All Affiliations

Blue Earth Diagnostics (United Kingdom)Emory University University of Pennsylvania Turku University Hospital University of Turku

About

Matthew P. Miller is an author at Blue Earth Diagnostics (United Kingdom) specializing in medical imaging, radiation oncology, and radiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	55
2	Engineering	1	1	22
3	Health Sciences	1	1	12
4	Public Health	1	1	22
5	Biomedical Engineering	1	1	22

Matthew P. Miller

Publications

894

Citations

H-Index

Page 1

	Year	Citations
Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand <sup>18</sup>F-AH111585 in Breast Cancer Patients Laura Kenny, R. Charles Coombes, Inger Oulie, Journal of Nuclear Medicine	2008	277
The Impact of Positron Emission Tomography with <sup>18</sup> F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial Gerald L. Andriole, Lale Kostakoğlu, Albert Chau, The Journal of Urology	2018	148
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE) Devaki Shilpa Surasi, Matthias Eiber, Tobias Maurer, European Urology	2023	86
The Biodistribution and Radiation Dosimetry of the Arg-Gly-Asp Peptide <sup>18</sup>F-AH111585 in Healthy Volunteers Brian J. McParland, Matthew P. Miller, T J Spinks, Journal of Nuclear Medicine	2008	66
Effect of 18F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: Results From the FALCON Trial Andrew Scarsbrook, David Bottomley, Eugene Teoh, International Journal of Radiation OncologyBiologyPhysics	2020	63
Diagnostic Performance and Safety of <sup>18</sup> F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT) Ashesh B. Jani, Gregory Ravizzini, Benjamin A. Gartrell, The Journal of Urology	2023	62
[18F]Fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ3 and αvβ5 integrins Esther Mena, Rikard Owenius, Barış Türkbey, European Journal of Nuclear Medicine and Molecular Imaging Renal TumorsHuman MelanomaMedicineMelanomaαVβ5 Integrins	2014	43
Safety, Biodistribution, and Radiation Dosimetry of <sup>18</sup>F-rhPSMA-7.3 in Healthy Adult Volunteers Tuula Tolvanen, Kari K. Kalliokoski, Simona Malaspina, Journal of Nuclear Medicine	2020	42
Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using <sup>18</sup>F-Fluciclovine PET/CT Matthew P. Miller, Lale Kostakoğlu, Daniel A. Pryma, Journal of Nuclear Medicine	2017	34
Multicenter Reproducibility of <sup>18</sup>F-Fluciclatide PET Imaging in Subjects with Solid Tumors Rohini Sharma, Kumar Kallur, Jin Sook Ryu, Journal of Nuclear Medicine	2015	23

Page 1